Compare · BBP vs HCXY
BBP vs HCXY
Side-by-side comparison of Virtus LifeSci Biotech Products ETF (BBP) and Hercules Capital, Inc. (HCXY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBP and HCXY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.54B.
- Over the past year, BBP is up 68.8% and HCXY is up 0.4% - BBP leads by 68.4 points.
- HCXY has hit the wire 1 time in the past 4 weeks while BBP has been quiet.
Virtus LifeSci Biotech Products ETF
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
Latest BBP
No recent items for Virtus LifeSci Biotech Products ETF.
Latest HCXY
- Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
- Hercules Capital Reports Second Quarter 2026 Financial Results
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026
- Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031
- Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031
- Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the First Quarter 2026